Fred D. Lublin, MD

Fred D. Lublin, MD

Saunders Family Professor of Neurology
Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Mount Sinai Medical Center
New York, New York

Disclosure Information:

Sources of Funding for Research: Acorda Therapeutics, Inc.; Biogen Idec; Genentech, Inc.; Novartis Pharmaceuticals Corp; Teva Neuroscience, Inc.
Consulting Agreements: Bayer HealthCare Pharmaceuticals; Biogen Idec; BioMS Medical Corp.; EMD Serono, Inc.; Genentech, Inc.; Medarex, Inc.; Novartis Pharmaceuticals Corp; Pfizer Inc; Teva Neuroscience, Inc.
Speakers’ Bureau/Honorarium Agreements: Bayer HealthCare Pharmaceuticals; EMD Serono, Inc.; Pfizer Inc; Teva Neuroscience, Inc.
Current Financial Interests/Stock Ownership: Cognition Therapeutics, Inc.
Discussion of Off-Label, Investigational, or Experimental Drug Use: None

Biography

Fred D. Lublin, MD, is the Saunders Family Professor of Neurology at Mount Sinai School of Medicine, New York, and Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at that institution. Dr. Lublin received his medical degree in 1972 from Jefferson Medical College, Philadelphia. He completed his internship in internal medicine at the Bronx Municipal Hospital, Albert Einstein Medical Center, and his residency at the New York Hospital, Cornell Medical Center.

As a neuroimmunologist, Dr. Lublin has a special interest in immune functions and abnormalities affecting the nervous system. He has been involved in both basic science and clinical research. He and his colleagues were among the first in the country to study IFN β-1b, which was approved by the Food and Drug Administration (FDA) in 1993 to treat the relapsing-remitting form of MS. He is currently involved with several new clinical research protocols on promising agents for treating various aspects of MS and is the principal investigator and national coordinating investigator for a multicenter National Institutes of Health–sponsored trial of combination therapy in MS. He was chairman of the National MS Society advisory committee on clinical trials of new drugs in multiple sclerosis and the National MS Society’s Research Programs Advisory Committee.

Dr. Lublin and his colleagues at the National MS Society have redefined the clinical course definitions of MS using data from a survey of the international MS community. He has chaired a task force on the ethics of placebo-controlled trials in MS and was a member of the panel that has redefined the diagnostic criteria for MS. Dr. Lublin has published numerous scientific articles and belongs to many professional societies and advisory boards. He has served as a consultant to the National Institutes of Health and to many pharmaceutical/biotech companies in all phases of new drug development and in preparation for presentation to the FDA and its advisory panels.